article thumbnail

Virtual Event: March of the Biosimilars

STAT

Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. Editor’s note: A livestream of this event will be embedded below at 1 p.m. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines?

article thumbnail

Opinion: STAT+: A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira

STAT

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was  followed by  eight additional adalimumab biosimilar launches. Biosimilars  are safe and effective treatments referencing biologic drugs. They If they fail to act, the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’

STAT

One such case occurred last year, when a wave of Humira biosimilars entered the market and drug companies slashed the list prices of their insulin products.

article thumbnail

Opinion: STAT+: The problem with potential changes to the biosimilar regulatory framework

STAT

Biosimilars are no longer a new and untested class of medicines. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S.,    37 biosimilars  have come to market offering the potential to increase patient choice and cost savings.

article thumbnail

STAT Virtual Event: The State of Biosimilars: What to Watch

STAT

Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings? What key signals will indicate how biosimilars might be prescribed, or paid for? Read the rest…

article thumbnail

STAT+: Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts

STAT

In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira — one of the world’s best-selling medicines — at a steep discount, and will work with Mark Cuban’s generic drug company to make the medicine available directly to consumers for even less.

article thumbnail

ASBM Releases Fact Sheet on Emerging Challenges to Interchangeable Biosimilars Policy

Safe Biologics

On January 31st, ASBM released a fact sheet describing a variety of proposed policy changes at the state and federal level which would weaken the interchangeable biosimilar standard, or circumvent the patient protections it provides.